Prof. Xinyan Zhao | Liver Injury | Best Researcher Award

Posted on by Pencis

Prof. Xinyan Zhao | Liver Injury | Best Researcher Award

Beijing Friendship Hospital, Capital Medical University | China

Author Profile

Scopus

Google Scholar

Biography of Xin Yan Zhao, M.D., Ph.D. ๐ŸŒŸ๐Ÿฉบ

Professor of Medicine | Head of Liver Research Center | Expert in Hepatology

Dr. Xin Yan Zhao is a distinguished Professor of Medicine and the Head of the Liver Research Center at Beijing Friendship Hospital, Capital Medical University, Beijing, China. She is also affiliated with the National Clinical Research Center for Digestive Disease, where she leads groundbreaking research in hepatology and liver transplantation pathology.

๐ŸŽ“ Education

  • M.D. (1995โ€“2000)
    Clinical Medicine, Capital Medical University, Beijing, China
  • M.S. (2000โ€“2003)
    Internal Medicine, Capital Medical University, Beijing, China
  • Ph.D. (2005โ€“2008)
    Hepatology, Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China

๐Ÿ‘ฉโ€โš•๏ธ Professional Experience

  • Head of Liver Research Center (2022โ€“Present)
    Beijing Friendship Hospital, Capital Medical University
  • Hepatologist & Clinical Liver Pathologist (2016โ€“2022)
    Beijing Friendship Hospital, Capital Medical University
  • Visiting Scholar (2015โ€“2016)
    Department of Liver and Transplant Pathology, University of Pittsburgh Medical Center, USA
  • Associate Professor (2014โ€“2015)
    Beijing Friendship Hospital, Capital Medical University
  • Attending Doctor, Department of Hepatology (2009โ€“2014)
    Beijing Friendship Hospital, Capital Medical University
  • Chief Resident of Internal Medicine (2008)
    Beijing Friendship Hospital, Capital Medical University
  • Resident of Internal Medicine (2003โ€“2007)
    Beijing Friendship Hospital, Capital Medical University

๐Ÿ† Awards and Honors

  • 2006: Excellent Paper Presentation Award, Chinese Society of Hepatology
  • 2008, 2010, 2013: Excellence in Teaching Award, Beijing Friendship Hospital
  • 2010: Award for Teaching Presentation and Skills in English, Capital Medical University
  • 2014: Excellent Young Investigator Award, APASL College, Beijing
  • 2018: Excellent Paper Presentation Award, Beijing Digestive Disease Weekend

๐ŸŒ Roles in Professional Societies

  1. Chairman (2024โ€“2025), Pathology Committee, International Liver Transplantation Society ๐ŸŒ
  2. Committee Member, Autoimmune Hepatitis Cooperation Group, Chinese Society of Hepatology
  3. Committee Member, Transplantation Pathology, Chinese Medical Doctor Association
  4. Committee Member, Digestive Pathology Cooperation Group, Chinese Society of Digestive Diseases

๐ŸŒ CONCLUSION

Dr. Xin Yan Zhao exemplifies excellence in medicine, research, and education. As a globally recognized leader in hepatology and liver transplantation pathology, she continues to drive innovation and collaboration in the field. Her dedication to advancing medical knowledge, training the next generation of physicians, and contributing to professional societies underscores her significant impact on liver research and clinical practice worldwide. ๐ŸŒŸ๐Ÿฉบ

๐Ÿ“Š๐Ÿ”ฌNOTABLE PUBLICATION:
  • Peridroplet mitochondria are associated with the severity of MASLD and the prevention of MASLD by diethyldithiocarbamate
    • Authors: Sun, X.; Yu, Q.; Qi, Y.; Cong, M.; Liu, T.
    • Journal: Journal of Lipid Research
    • Year: 2024

 

  • Autoimmune hepatitis with confluent necrosis indicates severe liver injury but responds well to standard immunosuppressive therapy
    • Authors: Sun, X.; Su, Y.; Wee, A.; Zhao, X.; Jia, J.
    • Journal: Histology and Histopathology
    • Year: 2024

 

  • Prevalence and clinical profiles of primary sclerosing cholangitis in China: Data from electronic medical records and systematic literature retrieval
    • Authors: Xu, X.; Meng, T.; Shi, L.; Jia, J.; Kong, Y.
    • Journal: Journal of Autoimmunity
    • Year: 2024

 

  • Multiscale X-ray phase-contrast CT uncovers adaptive changes and compensatory mechanisms of circulatory pathways during acute liver injury
    • Authors: Zhao, Y.; Lv, W.; He, Y.; Hu, C.; Jian, J.
    • Journal: Communications Biology
    • Year: 2024

 

  • Multiple Low-Level Viraemia Suggest Hindered Liver Fibrosis Regression in Chronic Hepatitis B Patients During Antiviral Therapy
    • Authors: Lu, Z.; Sun, Y.-M.; Chen, S.; Zhao, X.; You, H.
    • Journal: Journal of Viral Hepatitis
    • Year: 2024

Prof. Linghua Li | Cancer Science | Best Researcher Award

Posted on by Pencis

Prof. Linghua Li | Cancer Science | Best Researcher Award

Guangzhou Eighth People’s Hospital | China

Author Profile

ORCID ID

๐ŸŒŸLinghua Li, Ph.D., M.S., B.S. ๐ŸŒ

Head Director, Infectious Disease Center
Guangzhou Eighth Peopleโ€™s Hospital, Guangzhou Medical University

๐Ÿ‘ฉโ€โš•๏ธBiography

Dr. Linghua Li is a distinguished physician and researcher specializing in HIV/AIDS, infectious diseases, and oncology. With over 25 years of clinical experience, she has made significant contributions to understanding and managing infectious diseases, particularly fungal infections and HIV-related complications.

Dr. Li began her academic journey at the Medical School of Peking University, earning a B.S. in Clinical Medicine in 1997. She then pursued advanced studies at Sun Yat-sen University, completing an M.S. in Internal Medicine in 2008 and a Ph.D. in Infectious Diseases in 2011. She further enriched her expertise through visiting scholar positions at UNC-Chapel Hill (2012) and Duke University (2014), focusing on infectious diseases.

As the Head Director of the Infectious Disease Center at Guangzhou Eighth Peopleโ€™s Hospital, Dr. Li oversees clinical trials, patient care, and research initiatives for people living with HIV and at-risk populations. She has been principal investigator (PI) or co-investigator (Co-I) on more than 20 domestic and international research programs. Notable projects include:

  • National Natural Science Foundation of China (Grant No. 81301480): Investigating the mechanism and function of Phospholipase B in the growth and pathogenicity of P. marneffei.
  • Guangdong Natural Science Foundation (Grant No. 10151006002000000): Exploring the role of Phospholipase B in P. marneffei invasion of macrophages in AIDS patients.
  • NIH Fogarty Program: Examining host factors in severe opportunistic complications of AIDS, with a focus on developing targeted prophylactic strategies.

In recent years, Dr. Li has been a Co-PI on groundbreaking HIV PrEP Phase IV clinical trials in Guangzhou, including:

  • ChiCTR2100048981 and NCT04754139: These studies focus on scaling PrEP access for key populations in China. The trial successfully enrolled 1,007 participants by 2023, with 950 already on PrEP, marking it as the largest trial of its kind in China.

Dr. Liโ€™s work emphasizes translational medicine, data-driven public health strategies, and the implementation of novel interventions like PrEP to curb HIV transmission. Her expertise in site coordination, implementation, data collection, and analysis has been pivotal to these efforts.

๐ŸงฌKey Areas of Expertise

๐Ÿ”ฌ HIV Prevention and Treatment
๐ŸŒฟ Opportunistic Infections
๐Ÿ“Š Clinical Trials and Data Analysis
๐Ÿง‘โ€โš•๏ธ Internal and Infectious Diseases

๐Ÿ“šAcademic Background

  • B.S., Clinical Medicine, Medical School of Peking University (1997)
  • M.S., Internal Medicine, Sun Yat-sen University (2008)
  • Ph.D., Infectious Diseases, Sun Yat-sen University (2011)
  • Visiting Scholar, UNC-Chapel Hill (2012)
  • Visiting Scholar, Duke University (2014)

๐Ÿ”ฌResearch Impact

๐ŸŒŸ Over 20 funded research projects
๐Ÿ“„ Numerous publications in infectious disease and public health journals
๐Ÿ“š Active contributor to advancing HIV prevention strategies in China

Dr. Linghua Li remains a leader in the fight against infectious diseases, with a career dedicated to improving global health outcomes. ๐ŸŒโœจ

โœจ Conclusion

Dr. Linghua Li’s career exemplifies dedication to advancing the prevention, treatment, and understanding of infectious diseases, particularly HIV/AIDS and associated complications. Through her leadership, innovative research, and clinical expertise, she has significantly impacted global health, especially in developing effective interventions like PrEP for key populations in China. Her contributions to translational medicine and public health continue to pave the way for breakthroughs in managing infectious diseases and improving the lives of those affected worldwide. ๐ŸŒŸ๐ŸŒ

๐Ÿ“Š๐Ÿ”ฌNOTABLE PUBLICATION:
  • Utilizing Proteinโ€“Peptide Hybrid Microarray for Time-Resolved Diagnosis and Prognosis of COVID-19
    • Authors: Peiyan Zheng, Baolin Liao, Jiao Yang, Hu Cheng, Zhangkai Cheng, Huimin Huang, Wenting Luo, Yiyue Sun, Qiang Zhu, Yi Deng, et al.
    • Journal: Microorganisms
    • Year: 2023

Dr. Wenjin Wang | Targeted Cancer Therapy | Young Scientist Award

Posted on by Pencis

Dr. Wenjin Wang | Targeted Cancer Therapy | Young Scientist Award

The Chinese University of Hong Kong | China

Author Profile

Scopus

Dr. Wenjin Wang ๐ŸŒŸ๐Ÿ”ฌ

Postdoctoral Researcher | Tumor Photodynamic Therapy Expert | Biomolecular Phase Separation Investigator

Research Interests

  1. Tumor Photodynamic Therapy (PDT) ๐Ÿ’ก๐ŸŽฏ
    • Design and synthesis of novel photosensitizers for PDT.
    • Development of tumor-targeted PDT using tumor-responsive AIE (Aggregation-Induced Emission) photosensitizers.
  2. Regulation of Biomolecular Phase Separation ๐Ÿงฌโš›๏ธ
    • Investigation into the phase separation behaviors of biomolecules like proteins and nucleic acids.
    • Modulation of these processes with chemical molecules to enhance understanding of intracellular organization and function.

Professional Experience

  • Postdoctoral Researcher ๐Ÿข
    The Chinese University of Hong Kong, Shenzhen (07/2022โ€“Present)

    • Research on bioapplications of AIE materials under Prof. Ben Zhong Tang.
  • Biochemical Engineer ๐Ÿงช
    Shenzhen BGI Research Institute (10/2017โ€“09/2018)

    • Designed and optimized unnatural nucleotides for sequencing applications.
  • Laboratory Assistant ๐Ÿ”ฌ
    Peking University Shenzhen Graduate School (11/2016โ€“10/2017)

    • Focused on unnatural amino acids and asymmetric carbene O-H bond insertion catalysis by myoglobin proteins.
  • Research Associate ๐Ÿ’Š
    Tianjin Institute of Pharmaceutical Research (08/2014โ€“11/2016)

    • Developed new hypoglycemic drugs through innovative designs and research.

Education

  • Ph.D. in Chemical Biology ๐Ÿงซ
    Sun Yat-Sen University (09/2018โ€“06/2022)

    • Thesis: Antitumor mechanisms of metal complexes and their regulation on biomolecular phase separation behavior.
  • M.S. in Pharmacy ๐Ÿ’Š
    Tianjin Medical University (09/2012โ€“06/2015)

    • Research: Development of SGLT2 inhibitors and hypoglycemic activity evaluation.
  • B.S. in Pharmacy ๐Ÿฅ
    Tianjin Medical University (09/2008โ€“06/2012)

Grants and Funding ๐Ÿ’ฐ๐Ÿ“š

  1. National Natural Science Foundation of China
    • Ruthenium Complexes and Lipid Phase Separation in Antitumor Research (2024โ€“2026, RMB 300K, Principal Investigator).
  2. China Postdoctoral Science Foundation
    • GGT-Activated AIE Photosensitizers for Tumor Photodynamic Therapy (2022โ€“2025, RMB 80K, Principal Investigator).
  3. Shenzhen Medical Research Fund
    • Manipulable Aggregation of AIE Photosensitizers for Enhanced Tumor PDT (2025โ€“2027, RMB 800K, Principal Investigator).
  4. National Natural Science Foundation of China
    • Phase Separation Mechanism of Antitumor Phosphor Metal Complexes (2022โ€“2025, RMB 630K, Major Participant).
  5. Yunnan Province Science and Technology Plan
    • Aggregate Induced Luminescence in Biomass Resources (2024โ€“2026, RMB 2000K, Major Participant).

Awards and Honors ๐Ÿ†โœจ

  • Excellent Postdoctoral Doctor (Shenzhen, 12/2023).
  • National Scholarship for Doctoral Students (12/2021).
  • “Fran” Excellent Thesis Scholarship (Second Class, Sun Yat-sen University, 11/2021).
  • Excellent Wall Poster Award (32nd Academic Annual Meeting, Chinese Chemical Society, 04/2021).

Key Contributions ๐Ÿ“ˆ

Dr. Wangโ€™s groundbreaking research combines innovative photodynamic therapies and the manipulation of biomolecular phase separation, driving advancements in cancer treatment and molecular biology.

๐Ÿ“Š๐Ÿ”ฌNOTABLE PUBLICATION:
  • Title: Multi-Stimuli-Responsive and Cell Membrane Camouflaged Aggregation-Induced Emission Nanogels for Precise Chemo-photothermal Synergistic Therapy of Tumors
    • Authors: Zhang, L.; Wang, Z.; Zhang, R.; … Zhao, Z.; Tang, B.Z.
    • Journal: ACS Nano
    • Year: 2023

 

  • Title: Multi-site isomerization of synergistically regulated stimuli-responsive AIE materials toward multi-level decryption
    • Authors: Zhong, W.; Zhang, J.; Lin, Y.; … Cai, X.-M.; Tang, B.Z.
    • Journal: Chemical Science
    • Year: 2024

 

  • Title: Chromene-based BioAIEgens: โ€˜in-waterโ€™ synthesis, regiostructure-dependent fluorescence and ER-specific imaging
    • Authors: Cai, X.-M.; Lin, Y.; Zhang, J.; … Zhao, Z.; Tang, B.Z.
    • Journal: National Science Review
    • Year: 2023

 

  • Title: Natural Acceptor of Coumarin-Isomerized Red-Emissive BioAIEgen for Monitoring Cuยฒโบ Concentration in Live Cells via FLIM
    • Authors: Cai, X.-M.; Li, S.; Wang, W.-J.; … Zhao, Z.; Tang, B.Z.
    • Journal: Advanced Science
    • Year: 2024

 

  • Title: Room Temperature Phosphorescent Nanofiber Membranes by Bio-Fermentation
    • Authors: Nie, X.; Gong, J.; Ding, Z.; … Qiu, Z.; Tang, B.Z.
    • Journal: Advanced Science
    • Year: 2024

Prof. Zeng Qingjun | Gastrointestinal Tumors | Best Researcher Award

Posted on by Pencis

Prof. Zeng Qingjun | Gastrointestinal Tumors | Best Researcher Award

Yueyang Central Hospital | China

AUTHOR PROFILE

ORCID ID

๐Ÿ“šEARLY ACADEMIC PURSUITSย 

ZENG QINGJUN completed his Masterโ€™s degree at Xiangya Medical College, Central South University, in 2010. This prestigious institution provided a strong foundation in medical education, equipping him with the skills and knowledge necessary for his future in the field of gastrointestinal surgery. His academic training allowed him to develop expertise in complex surgical techniques, laying the groundwork for his career as a clinical specialist in surgery.

โš•๏ธPROFESSIONAL ENDEAVORSย 

Since July 2010, ZENG QINGJUN has been working in the field of gastrointestinal surgery, focusing on laparoscopic techniques for treating gastric and colorectal cancers. As a chief physician, he plays a pivotal role in leading surgical teams, performing high-risk surgeries, and making critical decisions for patient care. His clinical expertise and skillful handling of over 200 laparoscopic gastric cancer surgeries and 400 laparoscopic colorectal cancer surgeries are testaments to his proficiency in minimally invasive surgical methods. His surgical outcomes have contributed significantly to improving the quality of life for cancer patients and are recognized within the medical community.

๐Ÿ”ฌCONTRIBUTIONS AND RESEARCH FOCUS ON GASTROINTESTINAL TUMORS

Dr. ZENG has dedicated much of his professional life to the development and refinement of laparoscopic surgical techniques in the treatment of gastrointestinal cancers. His research is heavily focused on advancing minimally invasive surgery, particularly in the areas of gastric cancer and colorectal cancer. Through clinical trials and innovative methodologies, he has been involved in optimizing surgical procedures to ensure better postoperative recovery, reduced complications, and more efficient treatment pathways for cancer patients.

๐ŸŒIMPACT AND INFLUENCEย 

Dr. ZENG QINGJUN has made an immense impact on the practice of gastrointestinal surgery in China, particularly in the realm of laparoscopic surgery. His innovative approaches and commitment to cutting-edge techniques have influenced both local and national surgical practices. His contribution to gastric and colorectal cancer surgery has improved patient outcomes and has set new standards in the field. As a chief physician, he mentors younger surgeons and shares his expertise, ensuring the continued progress of surgical techniques.

๐Ÿ“‘ACADEMIC CITATIONSย 

While detailed citation metrics are not provided, Dr. ZENG’s extensive clinical experience and research endeavors have led to his recognition in academic circles. His focus on laparoscopic techniques and cancer surgery continues to influence current and future generations of surgeons and researchers in the field. His work, particularly in gastric and colorectal cancer, has made notable contributions to medical literature and has been referenced in various academic and clinical studies.

๐ŸŒฑLEGACY AND FUTURE CONTRIBUTIONSย 

Dr. ZENG QINGJUNโ€™s career reflects a legacy of excellence in surgical practice and medical innovation. His pioneering work in laparoscopic surgery and cancer treatment has already set the stage for future breakthroughs in the field of gastrointestinal oncology. Looking forward, he is likely to contribute even more significantly to surgical research, possibly expanding his focus to robot-assisted surgeries, postoperative care advancements, and the integration of AI in surgical planning. His mentorship, both locally and nationally, will shape the future of surgical education and the next generation of gastrointestinal surgeons.

๐Ÿ’ผLEADERSHIP IN SURGICAL PRACTICEย 

Dr. ZENG continues to hold a significant leadership role in the surgical department at his medical institution. His capacity as chief physician enables him to make high-level decisions in clinical practice, direct surgical teams, and implement best practice guidelines. His strategic leadership in gastrointestinal surgery helps to establish protocols for laparoscopic surgeries, improving surgical outcomes, and pushing the boundaries of traditional approaches.

๐Ÿ”— CONCLUSION

Dr. Zeng Qingjun is a distinguished gastrointestinal surgeon whose work has significantly advanced the field of laparoscopic surgery for gastric and colorectal cancers. With over a decade of experience and hundreds of successful surgeries, his contributions have set new standards in minimally invasive surgical techniques, improving patient outcomes and recovery times. Through his leadership as chief physician, he has not only influenced clinical practices but has also become a mentor to aspiring surgeons, ensuring the continuity of high-quality surgical education.

๐Ÿ“Š๐Ÿ”ฌNOTABLE PUBLICATION:
  • 1. Title: Knockdown of BUB1B Inhibits the Proliferation, Migration, and Invasion of Colorectal Cancer by Regulating the JNK/c-Jun Signaling Pathway
    Authors: Qingjun Zeng, Sanjun Zhang, Linfang He, Qingyan Fu, Li Liao, Linjie Chen, Xiang Ding
    Journal: Cancer Biotherapy and Radiopharmaceuticals
    Year: 2023

    2. Title: Targeting of MAD2L1 by miRโ€515โ€5p involves the regulation of cell cycle arrest and apoptosis of colorectal cancer cells
    Authors: Xiang Ding, Qingyan Fu, Weixing Chen, Linjie Chen, Qingjun Zeng, Sanjun Zhang, Linfang He
    Journal: Cell Biology International
    Year: 2022

Dr. Jun He | Stem Cell Therapy | Best Researcher Award

Posted on by Pencis

Dr. Jun He | Stem Cell Therapy | Best Researcher Award

The First Affiliated Hospital of Soochow University |ย  China

Author Profile

Scopus

Dr. Jun He appears to be a highly suitable candidate for the Research for Community Impact Award based on several key factors:

Extensive Professional Experience:

  • Leadership: Dr. He has been the Director of the HLA typing laboratory at the Jiangsu Institute of Hematology since 2010. This role indicates a significant leadership position within an influential research institution.
  • Long-term Commitment: Dr. He has held continuous positions of increasing responsibility at the same institution since 1985, showcasing dedication and consistent contribution to his field.

Educational Background:

  • Dr. He has a robust educational foundation in medicine, with both an M.D. and a B.S. from prestigious institutions in China (Soochow University and Suzhou Medical College).

Impactful Research:

  • Publication Record: Dr. He has published extensively in reputable peer-reviewed journals, with 33 listed publications. These papers cover critical aspects of HLA typing, stem cell transplantation, immunogenetics, and related fields, demonstrating significant contributions to medical science and community health.
  • Research Focus: His research on the genetic loci of HLA, KIRs, and their impact on transplantation outcomes is crucial for improving the success rates and safety of hematopoietic stem cell transplants, a vital area for many patients with hematological malignancies.

Professional Recognition and Membership:

  • Council Memberships: Dr. He has served as a Council Member for both the Experts Committee of the China Marrow Donor Program and The Chinese Medical Society of Organ Transplantation, indicating peer recognition and trust in his expertise.
  • International Membership: His membership in the American Society of Histocompatibility and Immunogenetics shows his engagement with the global scientific community.

Community Impact:

  • Marrow Donor Program: His long-term involvement with the China Marrow Donor Program reflects his commitment to enhancing donor registries and improving transplantation outcomes, directly benefiting patients and the broader community.
  • Training and Mentorship: As a Doctoral Supervisor, Dr. He plays a significant role in training the next generation of medical professionals and researchers, amplifying his impact on community health.

Innovative Research Contributions:

  • NGS and mNGS: His recent work using next-generation sequencing (NGS) and metagenomic NGS for pathogen identification demonstrates his engagement with cutting-edge technologies to improve clinical decision-making and patient outcomes.

In conclusion, Dr. Jun Heโ€™s distinguished career, significant research contributions, leadership roles, and dedication to community health make him a highly deserving candidate for the Research for Community Impact Award.

๐Ÿ“Š๐Ÿ”ฌNotable Publication:

    • Authors: Xu, J., Zhou, P., Liu, J., Ma, Y., He, J.
    • Journal: Infectious Diseases and Therapy
    • Year: 2023

 

    • Authors: Jiang, X., Yuan, X., Li, Y., Bao, X., He, J.
    • Journal: HLA
    • Year: 2023

 

    • Authors: Wang, L., Ji, K., Chen, L., Wu, X., He, J.
    • Journal: Frontiers in Immunology
    • Year: 2022

 

    • Authors: Zhou, S., Ma, X., Ma, C., Wu, X., Qin, S.
    • Journal: Bone Marrow Transplantation
    • Year: 2023

 

    • Authors: Cheng, Y., He, J., Zuo, B., He, Y.
    • Journal: Discover Oncology
    • Year: 2024

Dr. Lei Xia | Theranostics | Best Researcher Award

Posted on by Pencis

Dr. Lei Xia | Theranostics | Best Researcher Award

Peking University Cancer Hospital |ย  China

Author Profile

Scopus

Orcid Id

Dr. Xia Lei, PhD ๐Ÿงฌ

Affiliation:
Department of Nuclear Medicine, Peking University Cancer Hospital
Physician, Associate Researcher

Contact Information:
๐Ÿ“ž Phone: 18811177191
โœ‰๏ธ Email: xialei9012288@126.com

Biography:

Dr. Xia Lei, PhD, currently serves as a physician and associate researcher in the Department of Nuclear Medicine at Peking University Cancer Hospital. Dr. Lei graduated from the Medical School of Peking University in 2020. His expertise and research interests lie in the innovative field of nuclear medicine, particularly focusing on the development and clinical application of radiopharmaceutical probes for tumor targeting.

His primary research areas include:

  1. Construction of Tumor-Targeted Multimodal Imaging Molecular Probes ๐Ÿฉป
    • Dr. Lei is dedicated to creating advanced imaging probes that can target tumors with high precision, enhancing the accuracy of tumor detection and diagnosis.
  2. Development and Preliminary Application of Novel Integrated Diagnostic and Therapeutic Probes ๐Ÿงซ
    • He is pioneering the integration of diagnostic and therapeutic functions into single probes, aiming to streamline and improve the effectiveness of cancer treatment.
  3. Preparation and Clinical Translation of Tumor-Targeted Radiopharmaceutical Probes ๐Ÿงช
    • Dr. Lei’s work involves preparing radiopharmaceuticals that specifically target tumors and translating these innovations from the lab to clinical settings to benefit patients.

Principal Investigator in Projects:

Dr. Lei has been the principal investigator for several prestigious projects, showcasing his leadership in research and innovation:

  1. National Natural Science Foundation of China, Young Scientists Fund (NO.82202201) ๐ŸŒŸ
    • RMB 300,000 (January 2023 – December 2025)
  2. Young Talents Support Plan by the China Association for Science and Technology (NO. YESS20220230) ๐ŸŒŸ
    • RMB 600,000 (January 2023 – December 2025)
  3. Beijing Natural Science Foundation, General Program (NO.7242266) ๐ŸŒŸ
    • RMB 200,000 (January 2024 – December 2026)
  4. Peking University Cancer Hospital Science Innovation and Translation Fund ๐ŸŒŸ
    • RMB 140,000 (January 2024 – December 2024)
  5. Medical School of Peking University, Young Scientists Innovation Fund ๐ŸŒŸ
    • RMB 40,000
  6. Internal Fund of Peking University Cancer Hospital ๐ŸŒŸ
    • RMB 80,000
  7. Peking University Cancer Hospital Science Innovation Nurturing Fund ๐ŸŒŸ
    • RMB 100,000

Dr. Lei’s contributions to the field of nuclear medicine are instrumental in advancing the understanding and treatment of cancer, reflecting his commitment to medical innovation and patient care.

 

๐Ÿ“Š๐Ÿ”ฌNotable Publication:

 

 

 

 

Prof Shengping Hou |ย Immunotherapy | Best Researcher Award

Posted on by Pencis

Prof Shengping Hou | Immunotherapy | Best Researcher Award

Beijing Tongren Hospital, Capital Medical University | China

AUTHOR PROFILE

Scopus

Orcid ID

EARLY ACADEMIC PURSUITS

Shengping Hou, Ph.D., began his academic journey at Sun Yat-sen University in China, where he obtained his Ph.D. in Ocular Immunology in 2009. His doctoral research laid the foundation for his future contributions to ocular immunology, particularly focusing on the genetic aspects of ocular diseases. Following his Ph.D., Dr. Hou furthered his expertise with a postdoctoral fellowship at the University of California, San Francisco, specializing in Ocular Stem Cell Biology, which he completed in 2016.

PROFESSIONAL ENDEAVORS

Dr. Hou’s professional career commenced at The First Affiliated Hospital of Chongqing Medical University, where he served as an Associate Professor from 2009 to 2015. He was later promoted to Professor, a position he held until 2023. During his tenure, he was also a key figure at the Chongqing Key Laboratory of Ophthalmology. In 2023, Dr. Hou transitioned to Beijing Tongren Hospital, where he now serves as the Director of the Beijing Institute of Ophthalmology and continues his professorship at Capital Medical University.

CONTRIBUTIONS AND RESEARCH FOCUS ON IMMUNOTHERAPY

Dr. Hou’s research has primarily centered on the genetic and immunological underpinnings of ocular diseases, particularly uveitis and Behcetโ€™s disease. His work has involved extensive genetic studies, including the investigation of VKH syndrome and the role of complement component 4 copy number variants in ocular pathogenesis. His notable projects have been consistently supported by grants from the National Natural Science Foundation and other key R&D initiatives in China.

IMPACT AND INFLUENCE

Dr. Hou’s contributions have earned him significant recognition in the scientific community. He has been honored with several prestigious awards, including the First Prize for Achievement in Science and Technology from both Chongqing and the Chinese Health Ministry. His research findings have been widely disseminated through invited lectures and presentations at major international conferences, enhancing the understanding of genetic influences in ocular diseases.

ACADEMIC CITATIONS

Throughout his career, Dr. Hou has been an active member of the Chinese Ocular Immunology Society and has served as an ad hoc reviewer for several high-impact journals such as Nature Reviews Rheumatology, Advanced Science, and eBioMedicine. His work has been extensively cited by peers, reflecting the significant impact of his research on the field of ocular immunology.

LEGACY AND FUTURE CONTRIBUTIONS

Dr. Hou’s legacy in the field of ophthalmology is marked by his dedication to uncovering the genetic mechanisms underlying ocular diseases. As the Director of the Beijing Institute of Ophthalmology, he continues to lead groundbreaking research and mentor the next generation of scientists. His future contributions are poised to further advance the understanding and treatment of ocular conditions, solidifying his status as a leading figure in ophthalmic research.

NOTABLE PUBLICATION:

Citation: 36ย  ย  ย  ย  ย Year: 2023

Citation: 01ย  ย  ย  ย  Year: 2023

Cancer Drugs and Vaccines

Posted on by Pencis

Cancer Drugs and Vaccines

Introduction: Cancer Drugs and Vaccines are at the forefront of oncology research and treatment, offering promising solutions in the fight against cancer. These innovative therapies aim to improve patient outcomes, enhance survival rates, and provide hope for individuals battling this devastating disease.

Subtopics in Cancer Drugs and Vaccines:

Immunotherapy in Cancer Treatment: Immunotherapy harnesses the power of the immune system to target and destroy cancer cells. Explore the latest developments in checkpoint inhibitors, CAR-T cell therapy, and immune checkpoint blockade.

Targeted Therapies: Targeted cancer drugs are designed to specifically target cancer cells with minimal damage to healthy tissues. Delve into the mechanisms and effectiveness of these precision therapies.

Vaccine-Based Approaches: Investigate the role of cancer vaccines in preventing or treating various types of cancer. Discover the development and clinical trials of vaccines that stimulate the immune system to recognize and combat cancer cells.

Combination Therapies: Combinatorial approaches involving a mix of drugs, vaccines, and other treatments are gaining traction. Explore how these synergistic combinations are revolutionizing cancer care.

Personalized Medicine: Learn about the concept of tailoring cancer treatments to individual patients based on their genetic and molecular profiles. Explore the advancements in genomic medicine and its impact on cancer drug development.

Resistance Mechanisms: Understand the challenges posed by drug resistance in cancer treatment and how researchers are addressing these issues through innovative strategies.

Emerging Biomarkers: Discover the latest biomarkers used in cancer diagnosis, prognosis, and treatment selection, paving the way for more personalized and effective therapies.

Clinical Trials and Regulatory Challenges: Examine the critical role of clinical trials in evaluating the safety and efficacy of cancer drugs and vaccines, along with the regulatory processes that govern their approval.

Future Trends in Cancer Therapeutics: Explore the cutting-edge technologies and trends shaping the future of cancer treatment, from nanomedicine to gene editing and beyond.

Patient Perspectives and Support: Consider the holistic approach to cancer care, including patient support systems, psychosocial aspects, and quality of life improvements alongside drug and vaccine development.

Medical Oncology

Posted on by Pencis

Medical Oncology

Introduction to Medical Oncology: Medical Oncology is a specialized branch of medicine dedicated to the diagnosis, treatment, and management of cancer. This field plays a pivotal role in improving the lives of cancer patients through various treatment modalities and cutting-edge research. Within the realm of Medical Oncology, several key subtopics are essential for understanding and addressing the complexities of cancer care:

Chemotherapy and Targeted Therapies: Chemotherapy involves the use of drugs to kill or slow the growth of cancer cells, while targeted therapies focus on specific molecular abnormalities within cancer cells. Understanding these treatment options is crucial for medical oncologists to tailor therapies for individual patients.

Immunotherapy: Immunotherapy harnesses the body’s immune system to combat cancer. This groundbreaking approach has revolutionized cancer treatment by enhancing the body’s natural defenses against cancer cells.

Precision Medicine: Precision medicine in oncology involves customizing treatment plans based on a patient’s unique genetic and molecular profile. It allows for more personalized and effective cancer treatments, minimizing side effects.

Palliative Care: Palliative care in Medical Oncology is vital for improving the quality of life for cancer patients. It focuses on symptom management, pain relief, and emotional support to enhance patients’ overall well-being.

Clinical Trials and Research: Ongoing research and clinical trials are at the forefront of Medical Oncology. Investigating new treatments, therapies, and breakthroughs in cancer care is essential for improving patient outcomes and advancing the field.

These subtopics illustrate the multidimensional nature of Medical Oncology, where a comprehensive approach is taken to address the complexities of cancer treatment and patient care.